DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CRESTOR

Summary for Tradename: CRESTOR

Patents:5
Applicants:1
NDAs:1
Suppliers: see list12
2013 Sales:$5,310,818,000
drug
patent expirations by year for
 CRESTOR

Pharmacology for Tradename: CRESTOR

Clinical Trials for: CRESTOR

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)
Status: Completed Condition: Hypercholesterolemia

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
Status: Completed Condition: Hypertension; Hyperlipidemia

Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
Status: Completed Condition: Metabolic Syndrome

The Rosuvastatin In TrAnsplant Recipients Study
Status: Completed Condition: Disorder Related to Renal Transplantation; Hypercholesterolemia

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
Status: Completed Condition: Hypercholesterolemia; Dyslipidemia

A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects
Status: Completed Condition: Drug-Drug Interaction (DDI); Intestinal Absorption; Healthy Subjects; Pharmacokinetics of Rosuvastatin; Pharmacokinetics of Fidaxomicin

The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin
Status: Not yet recruiting Condition: Healthy

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
Status: Completed Condition: Dyslipidemia; Kidney Disease

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan
Status: Completed Condition: Hypertension; Hyperlipidemia

A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers
Status: Completed Condition: Pharmacokinetics and Drug Interaction of Crestor and Glucodown SR

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipr
CRESTOR
rosuvastatin calcium
TABLET;ORAL021366Aug 12, 2003RXNo6,316,460*PED<disabled>Y<disabled>
Ipr
CRESTOR
rosuvastatin calcium
TABLET;ORAL021366Aug 12, 2003RXNo6,858,618*PED<disabled>Y<disabled>
Ipr
CRESTOR
rosuvastatin calcium
TABLET;ORAL021366Aug 12, 2003RXNo7,030,152*PED<disabled>Y<disabled>
Ipr
CRESTOR
rosuvastatin calcium
TABLET;ORAL021366Aug 12, 2003RXNo7,964,614*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CRESTOR

Drugname Dosage Strength RLD Submissiondate
rosuvastatin calciumTablets5 mg, 10 mg, 20 mg and 40 mgCrestor8/13/2007

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc